ClinicalTrials.gg
CompletedNCT04818801Updated Sep 27, 2022

Safety, Reactogenicity and Immunogenicity Study of ReCOV

An Early Phase 1 interventional study of Recombinant two-component COVID-19 vaccine (CHO cell) and Placebo in Covid19, sponsored by Jiangsu Rec-Biotechnology Co., Ltd.. Completed at 2 sites in New Zealand. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-27.

Sponsored by Jiangsu Rec-Biotechnology Co., Ltd. · Early Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing CHO cell in COVID-19 — 1 open to participants now, 1 under way, none of them phase 3. CHO cell · COVID-19.

Enrollment
18th of 18
100 · median 714
Started
2021
with 8 others
Phase 1
2 of 18
none open now
Registered
3rd of 18
by date
Lead sponsor
4 of 18
Jiangsu Rec-Biotechnology Co., Ltd.

Among the 18 studies testing CHO cell in COVID-19, this one is the 18th largest by enrollment, is one of 9 that started in 2021, is one of 2 in phase 1, and was the 3rd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 18 studies testing CHO cell in COVID-19 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About CHO cell

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing CHO cell in COVID-19, or all of them as a file.
02

Study summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen that causes a coronavirus-associated acute respiratory disease called coronavirus disease 19 (COVID-19), which is spreading all over the world. This virus can cause acute respiratory distress syndrome (ARDS) with a high fatality rate.

In this phase I first-in-human clinical trial, healthy volunteers in two different age cohorts and two dose cohorts will be vaccinated twice with the candidate vaccine ReCOV.

The aim of the study is to assess the safety and reactogenicity of the candidate vaccine and to characterize its immunogenicity.

Read the detailed description

A total of 100 participants will receive the following vaccine regime:

First, 20 young adult participants (18 to 55 years old) will receive 20μg of ReCOV vaccine on days 0 and 21.

Then, 20 young adult participants (18 to 55 years old) will receive 40μg of ReCOV vaccine on days 0 and 21, and 20 old adult participants (56 to 80 years old) will receive 20μg of ReCOV vaccine on days 0 and 21.

Finally, 20 old adult participants (56 to 80 years old) will receive 40μg of ReCOV vaccine on days 0 and 21.

In the same time, 8 participants for each cohort, total 32 participants will receive 0.5ml of normal saline on days 0 and 21.

Safety and immunogenicity data will be collected throughout the study, which concludes at 12 month after the second dose.

03

Conditions studied

  • Covid19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects are eligible to be included in the study only if ALL of the following criteria apply at any time starting from Screening up to Day 1 prior to IP administration:

  1. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol.
  2. Male or female subjects who are ≥18 years old at the time of Screening (signing the ICF):

    1. For the younger adult group: 18 to 55 years, inclusive
    2. For the older adult group: ≥56 to \<80 years
  3. Have a (BMI) between 18.5 and 35.0 kg/m2.
  4. Subjects who are of general good health according to the Investigator's assessment, based on a complete medical history without major pathology, and as determined by medical evaluation (including physical examination, (ECG), vital signs, and clinical laboratory tests). Subjects in the older adult population who have medically stable, well-controlled comorbidities may be enrolled at the discretion of the Investigator.

    NOTE: All clinical laboratory values should be within reference ranges unless confirmed by Investigator or delegate as not . One repeat evaluation of ECG, vital signs, and clinical laboratory tests will be permitted, at the discretion of the Investigator.

  5. Subjects who test negative for surface antigen (HBsAg), hepatitis B core antibodies (anti-HBc), anti- virus (HCV) antibodies, and anti- (HIV) 1 and 2 antibodies at Screening.
  6. Subjects who test negative for SARS-Cov-2 infection, based on a reverse transcriptase polymerase chain reaction (RT-PCR) test and serological test for SARS-COV-2 IgM and/or IgG antibodies at Screening.
  7. Female subjects are eligible to participate if not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

    1. Is not a woman of (WOCBP), defined as:

      Surgically sterile (documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, as confirmed by review of the subject's medical records, medical examination, or medical history interview), or (defined as no menses for 12 months without an alternative medical cause. A high follicle-stimulating hormone [FSH] level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal or hormonal replacement therapy [HRT]. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient). Female subjects on HRT and whose menopausal status is in doubt will be required to use 1 of the non estrogen hormonal highly effective contraception methods from Day 1 until at least 6 months after the second dose of IP if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.

    2. Is a WOCBP who agrees to use a highly effective method of contraception consistently and correctly from Day 1 until at least 6 months after the second dose of IP.
  8. Nonsterilized male subjects with female partners of childbearing potential are eligible to participate if they agree to ONE of the following from Day 1 until at least 6 months after the second dose of IP and refrain from donating sperm during this period:

    1. Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.
    2. Agree to use a male condom and have their partner use of a contraceptive method with a failure rate of \<1% per year when having penile-vaginal intercourse with a WOCBP who is not currently pregnant.
    3. Male subjects with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration.

Exclusion criteria

Exclusion Criteria:

  • Subjects are excluded from the study if ANY of the following criteria apply at any time starting from Screening up to Day 1 prior to IP administration:

    1. History of and uncontrolled hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurologic disease in the opinion of the Investigator within 12 months prior to Screening.
    2. Individuals with behavioral or cognitive impairment in the opinion of the Investigator.
    3. Individuals with any progressive or severe neurologic disorder, seizure disorder, or history of Guillain-Barré syndrome.
    4. Individuals with known or suspected impairment of the immune system, such as:

      1. Use of systemic (oral or parenteral) for ≥14 consecutive days within 60 days prior to Day 1. Use of inhaled, intranasal, or topical corticosteroids is allowed. NOTE: Systemic (oral or parenteral) corticosteroids are also prohibited for 3 weeks after the second dose of the IP.
      2. Receipt of cancer chemotherapy within 5 years prior to Day 1.
      3. Receipt of immunostimulants or within 60 days prior to Day 1.
      4. Known or acquired immune deficiency syndrome.
      5. Subjects with active or prior documented disorder (such as potential immune mediated diseases [pIMDs]).
      6. Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Day 1 or planned during the full length of the study.
      7. Being treated for tuberculosis.
    5. History of allergic disease or reactions associated with previous vaccinations or likely to be exacerbated by any component of the IP.
    6. Individuals who have had a previous confirmed or suspected illness caused by SARS-CoV-1, SARS-CoV-2, or MERS-CoV.
    7. Individuals who have had a (excluding nonmelanotic skin cancer) or lymphoproliferative disorder within the past 5 years from the first dose of the IP (Day 1).
    8. History of urticaria within 1 year prior to Screening.
    9. History of hereditary angioneurotic edema or acquired angioneurotic edema.
    10. History of asplenia or functional asplenia.
    11. History of disorder or other bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the Investigator, contraindicate intramuscular injection.
    12. Current febrile illness or body temperature ≥38.0°C or other moderate to severe illness within 24 hours of IP administration on Day 1. This condition is considered to be temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met.
    13. Any current active infections, including localized infections, or any recent history (within 1 week prior to IP administration) of active infections or cough; or a history of recurrent or chronic infections (>3 infections/year).
    14. Individuals with a history of drug or alcohol abuse (with an average intake exceeding 10 drinks/week for women and 15 drinks/week for men: 1 drink = 360 mL of beer, 150 mL of wine, or 45 mL of spirits) or drug addiction (including soft drugs like cannabis products) within the past 2 years.
    15. Current heavy smoker, defined as smoking ≥20 cigarettes/day (1 pack or equivalent), or a former heavy smoker who was an active smoker within the past 1 year prior to Screening.
    16. Individuals who faint at the sight of blood or needles.
    17. Participation in another interventional clinical study (including a bioequivalence study) with an drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of the IP.
    18. Individuals who have received any prior investigational or approved vaccine against a coronavirus, including but not limited to SARS-CoV-1, SARS-CoV-2, and MERS-CoV.
    19. Individuals who have received any other licensed vaccines within 14 days (for inactivated vaccines) or 30 days (for live or attenuated vaccines) prior to enrollment in this study, or those who are planning to receive any vaccine within 30 days before the first dose of IP or during the study, with the exception of the seasonal influenza vaccine.
    20. Individuals must not have donated blood for 30 days prior to Day 1 and must agree to not donate blood for 6 months after Day 1 (receipt of first dose of the IP).
    21. Individuals with any condition that, in the opinion of the Investigator, would interfere with the study objectives or pose additional subject risk.
    22. Any persons who are:

      1. An employee of the study site, Investigator, contract research organization (CRO) or Sponsor.
      2. A first-degree relative of an employee of the study site, the Investigator, CRO, or the Sponsor.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Recombinant two-component COVID-19 vaccine (CHO cell)

    Participants received Recombinant two-component COVID-19 vaccine (CHO cell) 0.5ml reconstituted by adjuvant solution, 2 shots at a interval 21 days, intramuscular injection

    Biological: Recombinant two-component COVID-19 vaccine (CHO cell)

  • Placebo comparator
    Placebo

    Participants received placebo of 0.5ml normal saline (0.9% sodium chloride solution), 2 shots at a interval 21 days, intramuscular injection

    Other: Placebo

Interventions

  • The spike (S) protein is the main surface antigen of SARS-CoV-2, mediates entry of SARS CoV-2 into cells expressing the angiotensin-converting enzyme 2 (ACE2). The RBD interacts with ACE2 and can generate potent neutralizing anti-RBD antibodies.

    Also known as: ReCOV

  • OtherPlacebo

    Normal saline (0.9% sodium chloride solution),

    Also known as: Normal saline

06

What researchers measure

Primary outcomes

  1. Number of Participants with solicited local and systemic adverse events

    Incidence of solicited local and systemic adverse events up to 7 days after each dose

    Time frame: up to 7 days after each dose

  2. Number of Participants with unsolicited adverse events after each dose

    Incidence of unsolicited adverse events after each dose up to 30 days after the second dose

    Time frame: up to 30 days after the second dose

  3. Number of Participants with serious adverse events

    Incidence of serious adverse events up to 30 days after the second dose

    Time frame: up to 30 days after the second dose

  4. Number of Participants with changes in clinical laboratory tests from baseline

    Changes in clinical laboratory tests from baseline up to 7 days after each dose

    Time frame: up to 7 days after each dose

  5. Number of Participants with changes in vital signs from baseline

    Changes in vital signs from baseline up to 30 days after the second dose

    Time frame: up to 30 days after the second dose

Secondary outcomes

  1. Number of Participants with adverse events,serious adverse events, and adverse events of special interest

    Incidence of adverse events,serious adverse events, and adverse events of special interest up to 12 months after the second dose

    Time frame: up to 12 months after the second dose

  2. Number of Participants with changes in vital signs from baseline

    Changes in clinical laboratory tests and vital signs from baseline up to 12 months after the second dose

    Time frame: up to 12 months after the second dose

  3. Geometric mean titers(GMT)

    specific IgG binding antibodies against SARS-CoV-2

    Time frame: first dose day 21, second dose day 14, , day 30, day 90, day 180 and day 360

  4. Seroconversion rates

    specific IgG binding antibodies against SARS-CoV-2

    Time frame: first dose day 21, second dose day 14, , day 30, day 90, day 180 and day 360

  5. Geometric mean fold increase

    specific IgG binding antibodies against SARS-CoV-2

    Time frame: first dose day 21, second dose day 14, , day 30, day 90, day 180 and day 360

  6. IFN-γ

    Positivity rate of IFN-γ measured by ELISpot

    Time frame: first dose day 21, second dose day 14, , day 30, day 90, day 180 and day 360

  7. Geometric mean titers(GMT)

    specific IgG neutralizing antibodies against SARS-CoV-2

    Time frame: first dose day 21, second dose day 14, , day 30, day 90, day 180 and day 360

  8. Seroconversion rates

    specific IgG neutralizing antibodies against SARS-CoV-2

    Time frame: first dose day 21, second dose day 14, , day 30, day 90, day 180 and day 360

  9. Geometric mean fold increase

    specific IgG neutralizing antibodies against SARS-CoV-2

    Time frame: first dose day 21, second dose day 14, , day 30, day 90, day 180 and day 360

  10. Levels of other T cell biomarkers

    CD4+/CD8+ counts, IL-4, IL-5, and IL-17

    Time frame: first dose day 21, second dose day 14, , day 30, day 90, day 180 and day 360

07

Study locations

2 sites
  • Auckland Clinical Studies
    Auckland, New Zealand
  • Christchurch Clinical Studies Trust
    Christchurch, New Zealand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in May 2022, 10 months.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 10 months is above that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2021
First posted
Mar 26, 2021
StartActual
Jun 18, 2021
Primary completionActual
May 5, 2022
CompletionActual
May 5, 2022
Last update
Sep 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04818801
Lead sponsor
Jiangsu Rec-Biotechnology Co., Ltd.
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Mar 26, 2021
Start date
Jun 18, 2021
Primary completion
May 5, 2022
Completion
May 5, 2022
Last update
Sep 27, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CHO cell

Start the discussion